Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

Exclusion Criteria

• •1. Mixed small cell and non-small cell lung cancer histology.
• •2. Any unresolved toxicity\>CTCAE grade 2 from previous anti-cancer therapy.
• •3. Patients with exposure to biotherapy, immunotherapy within 4 weeks of study entry.
• •4. Other concurrent anticancer therapy.
• •5. Patients with exposure to investigational drug therapy outside of this trial.
• •6. Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease.
• •7. Any unstable systemic disease (including active infection, hepatic, renal, metabolic disease or seizure disorder requiring medication).
• •8. Significant cardiovascular event: congestive heart failure \>NYHA class 2; unstable angina, active CAD (myocardial infarction more than 1 year prior to study entry is allowed); serious cardiac arrhythmia requiring anti-arrhythmic therapy ( beta blockers or digoxin are permitted) or uncontrolled hypertension.
• •9. Brain metastases or spinal cord compression, if treated before the start of study treatment, and have any symptoms. Symptoms include signs of increased intracranial pressure ,headache,nausea and vomiting,cognitive or affective disturbances,seizures,and focal neurologic symptoms.
• •10. History of another malignancy within the last 5 years except cured carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and superficial bladder tumors \[Ta, Tis \& T1\].
• •11. Pregnant or breast-feeding women.
• •12. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
• •13. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.